

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Fig. 1 (A)








Fig. 1 (B)




~53kDa spot is increased MCF-7/AR




**Fig. 3 (A)** CEM




**Fig. 3 (B)** CEM/VLB




**Fig. 4 (A)**




**Fig. 4 (B)**




**Fig. 4 (C)**




**Fig. 4 (D)**




**Fig. 5 A**




**Fig. 5 B**



**Fig. 5 C**



**Fig. 5 D**






Fig. 6




Fig. 7






Fig. 8




Fig. 9



Fig.10




Fig. 11

## FIGURE 12

A

### POLYPEPTIDE SEQUENCE OF HUMAN VIMENTIN

(GENBANK ACCESSION NO. P08670 (SEQ ID NO. ))

```
1  MSTRSVSSSS YRRMFGGPGT ASRPSSRSY VTTSTRTYSL GSALRPSTSR SLYASSPGGV
61  YATRSSAVRL RSSVPGVRL QDSVDFSLAD AINTEFKNTR TNEKVELQEL NDRFANYIDK
121 VRFLEQQNKI LLAELEQLKG QGKSRLGDLY EEEMRELRRQ VDQLTNDKAR VEVERDNLAE
181 DIMRLREKLQ EEMLQREEAE NTLQSFQDV DNASLARLDL ERKVESLQEE IAFLKKLHEE
241 EIQELQAQIQ EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEW YKSKFADLSE
301 AANRRNDALR QAKQESTEYR RQVQSLTCEV DALKGTNESL ERQMREMEEN FAVEAANYQD
361 TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY RKLLEGEESR ISLPLPNFSS
421 LNLRETNLDS LPLVDTHSKR TFLIKTVETR DGQVINETSQ HHDDLE
```

B

### NUCLEIC ACID SEQUENCE OF HUMAN VIMENTIN

(GENBANK ACCESSION NO. X56134 (SEQ ID NO. ))

```
1  CGCGCCACCG CCGCCGCCCA GGCCATCGCC ACCCTCCGCA GCCATGTCCA CCAGGTCCGT
61  GTCCTCGTCC TCCTACCGCA GGATGTTTCG CGGCCCGGGC ACCGCGAGCC GGCCGAGCTC
121 CAGCCGGAGC TACGTGACTA CGTCCACCCG CACCTACAGC CTGGGCAGCG CGCTGCGCCC
181 CAGCACCAGC CGCAGCCTCT ACGCCTCGTC CCCGGGCGGC GTGTATGCCA CGCGCTCCTC
241 TGCCGTGCGC CTGCGGAGCA GCGTGCCCGG GGTGCGGCTC CTGCAGGACT CGGTGGACTT
```

301 CTCGCTGGCC GACGCCATCA ACACCGAGTT CAAGAACACC CGCACCAACG AGAAGGTGGA  
361 GCTGCAGGAG CTGAATGACC GCTTCGCCAA CTACATCGAC AAGGTGCGCT TCCTGGAGCA  
421 GCAGAATAAG ATCCTGCTGG CCGAGCTCGA GCAGCTCAAG GGCCAAGGCA AGTCGCGCCT  
481 GGGGGACCTC TACGAGGAGG AGATGCGGGA GCTGCGCCGG CAGGTGGACC AGCTAACCAA  
541 CGACAAAGCC CGCGTCGAGG TGGAGCGCGA CAACCTGGCC GAGGACATCA TGCGCCTCCG  
601 GGAGAAATTG CAGGAGGAGA TGCTTCAGAG AGAGGAAGCC GAAAACACCC TGCAATCTTT  
661 CAGACAGGAT GTTGACAATG CGTCTCTGGC ACGTCTTGAC CTTGAACGCA AAGTGGAATC  
721 TTTGCAAGAA GAGATTGCCT TTTTGAAGAA ACTCCACGAA GAGGAAATCC AGGAGCTGCA  
781 GGCTCAGATT CAGGAACAGC ATGTCCAAAT CGATGTGGAT GTTTCCAAGC CTGACCTCAC  
841 GGCTGCCCTG CGTGACGTAC GTCAGCAATA TGAAAGTGTG GCTGCCAAGA ACCTGCAGGA  
901 GGCAGAAGAA TGGTACAAAT CCAAGTTTGC TGACCTCTCT GAGGCTGCCA ACCGGAACAA  
961 TGACGCCCTG CGCCAGGCAA AGCAGGAGTC CACTGAGTAC CGGAGACAGG TGCAGTCCCT  
1021 CACCTGTGAA GTGGATGCCC TTAAAGGAAC CAATGAGTCC CTGGAACGCC AGATGCGTGA  
1081 AATGGAAGAG AACTTTGCCG TTGAAGCTGC TAACTACCAA GACACTATTG GCCGCCTGCA  
1141 GGATGAGATT CAGAATATGA AGGAGGAAAT GGCTCGTCAC CTTCGTGAAT ACCAAGACCT  
1201 GCTCAATGTT AAGATGGCCC TTGACATTGA GATTGCCACC TACAGGAAGC TGCTGGAAGG  
1261 CGAGGAGAGC AGGATTTCTC TGCCTCTTCC AAAC'TTTTCC TCCCTGAACC TGAGGGAAAC  
1321 TAATCTGGAT TCACTCCCTC TGGTTGATAC CCACTCAAAA AGGACACTTC TGATTAAGAC  
1381 GGT'TGAAACT AGAGATGGAC AGGTTATCAA CGAAACTTCT CAGCATCACG ATGACCTTGA  
1441 ATAAAAAATTG CACACACTCA GTGCAGCAAT ATATTACCAG CAAGAATAAA AAAGAAATCC  
1501 ATATCTTAAA GAAACAGCTT TCAAGTGCCT TTCTGCAGTT TTTCAGGAGC GCAAGATAGA  
1561 TTTGGAATAG GAATAAGCTC TAGTTCTTAA CAACCGACAC TCCTACAAGA TTTAGAAAAA  
1621 AGTTTACAAC ATAATCTAGT TTACAGAAAA ATCTTGTGCT AGAATACTTT TTTAAAGGTA  
1681 TTTTGAATAC CATTAAAACT GCTTTTTTTTTT TTCCAGCAAG TATCCAACCA ACTTGGTTCT  
1741 GCTTCAATAA ATCTTTGGAA AAAC TA

**Figure 13A : Procedure for immunofluorescence (non-permeabilized cells)**




Figure 13B: Procedure for immunofluorescence (permeabilized cells)






Figure 14

Non  
permeabilized


Permeabilized



MCF-7

MCF-7/AR

Figure 15



LS-11-15-03

Figure 16





Figure 17




17A

Expt	MDA/mito (epitopes)	Kd (nM)	r <sup>2</sup>
1	2764751	10.4	0.95
2	3477797	5.9	0.97
3	1496035	2.5	0.98
4	2720065	3.2	0.97
5	2012848	6.7	0.97
Ave	2494299	5.7	
Std	761530	3.1	

17C

cells	AVE	STD	Kd	R/S
MCF-7	9.1.E+03	8.8.E+03	nd	
MCF-7/AR	3.8.E+05	1.1.E+05	nd	41.2
MDA	6.3.E+05	1.6.E+05	9.3 ± 2.8	
MDA/mito	2.5.E+06	7.6.E+05	5.7 ± 3.1	4.0
SKOV3	7.4.E+05	3.7.E+05	nd	
SKOV/T320	1.2.E+06	2.0.E+05	nd	1.6
2008	4.1.E+04	2.2.E+04	nd	
2008/T320	8.3.E+04	1.3.E+04	nd	2.0

Figure 18



# Figure 19

